Drug Trial Radar · NCT01494467
Phase 3 Papulopustular Rosacea Study
Last checked: Nov 19, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
688
Actual
Start
Dec 2011
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Conditions
- Papulopustular Rosacea
Interventions
CD5024Drug
CD5024 1% Cream, once daily
Azelaic acid 15% GelDrug
Topical Gel applied twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Success RateTime frame: Week 12
- Absolute Change in Inflammatory Lesion CountTime frame: Baseline to Week 12
Locations
50 sites in 2 countries. Site status is shown where the registry gives one.
Total Skin and Beauty
Birmingham, Alabama
Coastal Clinical Research, Inc.
Mobile, Alabama
Burke Pharmaceutical Research
Hot Springs, Arkansas
Dermatology Specialists, Inc
Oceanside, California
Integrated Research Group, Inc
Riverside, California
Therapeutics Clinical Research
San Diego, California
University of California, San Francisco
San Francisco, California
ATS Clinical Research
Santa Monica, California
Redwood Dermatology Research
Santa Rosa, California
FXM Research Corp Miami
Miami, Florida
Leavitt Medical Associates of Florida dba Ameriderm Research
Ormond Beach, Florida
Atlanta Dermatology, Vein & Research Center, LLC
Alpharetta, Georgia
Emory University
Atlanta, Georgia
Altman Dermatology Associates
Arlington Heights, Illinois
Northwestern University
Chicago, Illinois
Deaconess Clinic, Inc.
Evansville, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Dermatology Specialists Research
Louisville, Kentucky
Northeast Dermatology Associates
Beverly, Massachusetts
David Fivenson, MD, PLC
Ann Arbor, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Somerset Skin Centre
Troy, Michigan
Dermatology Clinical Trials Unit
St Louis, Missouri
Psoriasis Treatment Center of NJ
West Windsor, New Jersey
Academic Dermatology Associates
Albuquerque, New Mexico
DermResearch Center of New York, Inc
Stony Brook, New York
Site not named
High Point, North Carolina
PMG Research of Raleigh, LLC
Raleigh, North Carolina
Oregon Dermatology and Research Center
Portland, Oregon
Dermatology and Skin Surgery Center
Exton, Pennsylvania
Philadelphia Institute of Dermatology
Fort Washington, Pennsylvania
Penn State Hershey Medical Center
Hershey, Pennsylvania
Paddington Research
Philadelphia, Pennsylvania
Yardley Dermatology Associates
Yardley, Pennsylvania
The Skin Wellness Center
Knoxville, Tennessee
Dermatology Reserach Associates
Nashville, Tennessee
Arlington Research Center, Inc
Arlington, Texas
Stephen Miller MD
San Antonio, Texas
Site not named
San Antonio, Texas
Center for Clinical Studies
Webster, Texas
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.